Skip to main content
Erschienen in: American Journal of Cardiovascular Drugs 5/2010

01.10.2010 | Original Research Article

An Olmesartan Medoxomil-Based Treatment Algorithm is Effective in Achieving 24-Hour BP Control in Patients with Type 2 Diabetes Mellitus, Regardless of Age, Race, Sex, or Severity of Hypertension

Subgroup Analysis of the BENIFICIARY Study

verfasst von: Dr Joel M. Neutel, Dean J. Kereiakes, The BENIFICIARY Investigators

Erschienen in: American Journal of Cardiovascular Drugs | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Hypertension often occurs concomitantly with diabetes mellitus, such that >50% of adults with type 2 diabetes have hypertension. These individuals are at a greater risk of developing renal and cardiovascular disease. The currently recommended BP goal of <130/80 mmHg for patients with type 2 diabetes is achieved in only 37.5% of treated patients with diabetes and hypertension.

Methods

The antihypertensive efficacy of olmesartan medoxomil (OM) ± hydrochlorothiazide (HCTZ) was investigated in prespecified subgroups (age <65/≥65 years, Blacks/non-Blacks, males/females, or stage 1/ stage 2 hypertension) of patients with hypertension and type 2 diabetes enrolled in an open-label, single-arm study (n= 192). Patients started treatment with OM 20 mg/day and were uptitrated at 3-week intervals to OM 40, OM/HCTZ 40/12.5, and OM/HCTZ 40/25 mg/day if BP was ≥120/70 mmHg. The primary endpoint was the change in mean 24-hour ambulatory SBP from baseline to week 12, assessed by mean 24-hour ambulatory BP monitoring. Secondary endpoints included changes in mean 24-hour ambulatory DBP, mean daytime ambulatory BP, mean nighttime ambulatory BP, and mean office seated BP, and the proportions of patients achieving prespecified ambulatory BP targets.

Setting

This was a multicenter study (24 sites) that took place between November 2006 and November 2007 in the US.

Results

BP reductions were significant (p < 0.0001) and similar among subgroups of patients with type 2 diabetes. Following dose titration to OM/HCTZ 40/25 mg/day, similar proportions of patients in the age, race, and sex subgroups (approximately 60–64% across these subgroups) achieved an ambulatory BP target of <130/80 mmHg. A larger proportion of patients with type 2 diabetes and stage 1 hypertension achieved this same goal compared with patients with stage 2 hypertension (75% vs 46.3%). The combination of OM/HCTZ was well tolerated in all patient subgroups irrespective of age, race, sex, or hypertension severity.

Conclusions

In this open-label study, OM/HCTZ combination therapy was efficacious and well tolerated in subgroups of patients with diabetes and hypertension.
[Clinical Trials Registry Number: NCT00403481]
Literatur
1.
Zurück zum Zitat Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics — 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008 Jan 29; 117(4): e25–146.PubMedCrossRef Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics — 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008 Jan 29; 117(4): e25–146.PubMedCrossRef
2.
Zurück zum Zitat Kabakov E, Norymberg C, Osher E, et al. Prevalence of hypertension in type 2 diabetes mellitus: impact of the tightening definition of high blood pressure and association with confounding risk factors. J Cardiometab Syndr 2006 Spring; 1(2): 95–101.PubMedCrossRef Kabakov E, Norymberg C, Osher E, et al. Prevalence of hypertension in type 2 diabetes mellitus: impact of the tightening definition of high blood pressure and association with confounding risk factors. J Cardiometab Syndr 2006 Spring; 1(2): 95–101.PubMedCrossRef
3.
Zurück zum Zitat Resnick HE, Foster GL, Bardsley J, et al. Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999–2002: the National Health and Nutrition Examination Survey. Diabetes Care 2006 Mar; 29(3): 531–7.PubMedCrossRef Resnick HE, Foster GL, Bardsley J, et al. Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999–2002: the National Health and Nutrition Examination Survey. Diabetes Care 2006 Mar; 29(3): 531–7.PubMedCrossRef
4.
Zurück zum Zitat Arauz-Pacheco C, Parrott MA, Raskin P. The treatment of hypertension in adult patients with diabetes. Diabetes Care 2002 Jan; 25(1): 134–47.PubMedCrossRef Arauz-Pacheco C, Parrott MA, Raskin P. The treatment of hypertension in adult patients with diabetes. Diabetes Care 2002 Jan; 25(1): 134–47.PubMedCrossRef
5.
Zurück zum Zitat Legato MJ, Gelzer A, Goland R, et al. Gender-specific care of the patient with diabetes: review and recommendations. Gend Med 2006 Jun; 3(2): 131–58.PubMedCrossRef Legato MJ, Gelzer A, Goland R, et al. Gender-specific care of the patient with diabetes: review and recommendations. Gend Med 2006 Jun; 3(2): 131–58.PubMedCrossRef
6.
Zurück zum Zitat American Diabetes Association. Standards of medical care in diabetes — 2008. Diabetes Care 2008 Jan; 31 Suppl. 1: S12–54.CrossRef American Diabetes Association. Standards of medical care in diabetes — 2008. Diabetes Care 2008 Jan; 31 Suppl. 1: S12–54.CrossRef
7.
Zurück zum Zitat Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 Dec; 42(6): 1206–52.PubMedCrossRef Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 Dec; 42(6): 1206–52.PubMedCrossRef
8.
Zurück zum Zitat Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007 Jun; 25(6): 1105–87.PubMedCrossRef Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007 Jun; 25(6): 1105–87.PubMedCrossRef
9.
Zurück zum Zitat Rodbard H, Blonde L, Braithwaite S, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007 May–Jun; 13 Suppl. 1: 1–68.PubMed Rodbard H, Blonde L, Braithwaite S, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007 May–Jun; 13 Suppl. 1: 1–68.PubMed
10.
Zurück zum Zitat Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension 2007 Jan; 49(1): 69–75.PubMedCrossRef Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension 2007 Jan; 49(1): 69–75.PubMedCrossRef
11.
Zurück zum Zitat McFarlane SI, Jacober SJ, Winer N, et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 2002 Apr; 25(4): 718–23.PubMedCrossRef McFarlane SI, Jacober SJ, Winer N, et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 2002 Apr; 25(4): 718–23.PubMedCrossRef
12.
Zurück zum Zitat Pessina AC. Target organs of individuals with diabetes caught between arterial stiffness and damage to the microcirculation. J Hypertens 2007 Jun; 25 Suppl. 1: S13–8.CrossRef Pessina AC. Target organs of individuals with diabetes caught between arterial stiffness and damage to the microcirculation. J Hypertens 2007 Jun; 25 Suppl. 1: S13–8.CrossRef
13.
Zurück zum Zitat Neutel JM, Kereiakes DJ, Waverczak WF, et al. Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes. Curr Med Res Opin 2010 Mar; 26(3): 721–8.PubMedCrossRef Neutel JM, Kereiakes DJ, Waverczak WF, et al. Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes. Curr Med Res Opin 2010 Mar; 26(3): 721–8.PubMedCrossRef
14.
Zurück zum Zitat Jula A, Puukka P, Karanko H. Multiple clinic and home blood pressure measurements versus ambulatory blood pressure monitoring. Hypertension 1999 Aug; 34(2): 261–6.PubMedCrossRef Jula A, Puukka P, Karanko H. Multiple clinic and home blood pressure measurements versus ambulatory blood pressure monitoring. Hypertension 1999 Aug; 34(2): 261–6.PubMedCrossRef
15.
Zurück zum Zitat Mancia G, Parati G. Ambulatory blood pressure monitoring and organ damage. Hypertension 2000 Nov; 36(5): 894–900.PubMedCrossRef Mancia G, Parati G. Ambulatory blood pressure monitoring and organ damage. Hypertension 2000 Nov; 36(5): 894–900.PubMedCrossRef
16.
Zurück zum Zitat Mancia G, Parati G, Hennig M, et al. Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens 2001 Nov; 19(11): 1981–9.PubMedCrossRef Mancia G, Parati G, Hennig M, et al. Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens 2001 Nov; 19(11): 1981–9.PubMedCrossRef
17.
Zurück zum Zitat Mancia G, Zanchetti A, Agabiti-Rosei E, et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. Circulation 1997 Mar 18; 95(6): 1464–70.PubMedCrossRef Mancia G, Zanchetti A, Agabiti-Rosei E, et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. Circulation 1997 Mar 18; 95(6): 1464–70.PubMedCrossRef
18.
Zurück zum Zitat Neutel JM. The importance of 24-h blood pressure control. Blood Press Monit 2001 Feb; 6(1): 9–16.PubMedCrossRef Neutel JM. The importance of 24-h blood pressure control. Blood Press Monit 2001 Feb; 6(1): 9–16.PubMedCrossRef
19.
Zurück zum Zitat Fliser D, Wagner KK, Loos A, et al. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. J Am Soc Nephrol 2005 Apr; 16(4): 1135–40.PubMedCrossRef Fliser D, Wagner KK, Loos A, et al. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. J Am Soc Nephrol 2005 Apr; 16(4): 1135–40.PubMedCrossRef
20.
Zurück zum Zitat Nakayama S, Watada H, Mita T, et al. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension. Hypertens Res 2008 Jan; 31(1): 7–13.PubMedCrossRef Nakayama S, Watada H, Mita T, et al. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension. Hypertens Res 2008 Jan; 31(1): 7–13.PubMedCrossRef
21.
Zurück zum Zitat Fukuda M, Yamanaka T, Mizuno M, et al. Angiotensin II type 1 receptor blocker, olmesartan, restores nocturnal blood pressure decline by enhancing daytime natriuresis. J Hypertens 2008 Mar; 26(3): 583–8.PubMedCrossRef Fukuda M, Yamanaka T, Mizuno M, et al. Angiotensin II type 1 receptor blocker, olmesartan, restores nocturnal blood pressure decline by enhancing daytime natriuresis. J Hypertens 2008 Mar; 26(3): 583–8.PubMedCrossRef
22.
Zurück zum Zitat Kereiakes DJ, Neutel J, Stoakes KA, et al. The effects of an olmesartan medoxomil-based treatment algorithm on 24-hour blood pressure levels in patients aged 65 and older. J Clin Hypertens (Greenwich) 2009; 11: 1–11.CrossRef Kereiakes DJ, Neutel J, Stoakes KA, et al. The effects of an olmesartan medoxomil-based treatment algorithm on 24-hour blood pressure levels in patients aged 65 and older. J Clin Hypertens (Greenwich) 2009; 11: 1–11.CrossRef
23.
Zurück zum Zitat Chavanu K, Merkel J, Quan AM. Role of ambulatory blood pressure monitoring in the management of hypertension. Am J Health Syst Pharm 2008 Feb 1; 65(3): 209–18.PubMedCrossRef Chavanu K, Merkel J, Quan AM. Role of ambulatory blood pressure monitoring in the management of hypertension. Am J Health Syst Pharm 2008 Feb 1; 65(3): 209–18.PubMedCrossRef
24.
Zurück zum Zitat Manios ED, Koroboki EA, Tsivgoulis GK, et al. Factors influencing whitecoat effect. Am J Hypertens 2008 Feb; 21(2): 153–8.PubMedCrossRef Manios ED, Koroboki EA, Tsivgoulis GK, et al. Factors influencing whitecoat effect. Am J Hypertens 2008 Feb; 21(2): 153–8.PubMedCrossRef
25.
Zurück zum Zitat Palatini P. Too much of a good thing? A critique of overemphasis on the use of ambulatory blood pressure monitoring in clinical practice. J Hypertens 2002 Oct; 20(10): 1917–23.PubMedCrossRef Palatini P. Too much of a good thing? A critique of overemphasis on the use of ambulatory blood pressure monitoring in clinical practice. J Hypertens 2002 Oct; 20(10): 1917–23.PubMedCrossRef
26.
Zurück zum Zitat Sega R, Cesana G, Milesi C, et al. Ambulatory and home blood pressure normality in the elderly: data from the PAMELA population. Hypertension 1997 Jul; 30(1 Pt 1): 1–6.PubMedCrossRef Sega R, Cesana G, Milesi C, et al. Ambulatory and home blood pressure normality in the elderly: data from the PAMELA population. Hypertension 1997 Jul; 30(1 Pt 1): 1–6.PubMedCrossRef
27.
Zurück zum Zitat Calvo C, Hermida RC, Ayala DE, et al. The ‘ABPM effect’ gradually decreases but does not disappear in successive sessions of ambulatory monitoring. J Hypertens 2003 Dec; 21(12): 2265–73.PubMedCrossRef Calvo C, Hermida RC, Ayala DE, et al. The ‘ABPM effect’ gradually decreases but does not disappear in successive sessions of ambulatory monitoring. J Hypertens 2003 Dec; 21(12): 2265–73.PubMedCrossRef
28.
Zurück zum Zitat Pang TC, Brown MA. Accuracy of ambulatory blood pressure monitors in routine clinical practice. Am J Hypertens 2006 Aug; 19(8): 801–9.PubMedCrossRef Pang TC, Brown MA. Accuracy of ambulatory blood pressure monitors in routine clinical practice. Am J Hypertens 2006 Aug; 19(8): 801–9.PubMedCrossRef
Metadaten
Titel
An Olmesartan Medoxomil-Based Treatment Algorithm is Effective in Achieving 24-Hour BP Control in Patients with Type 2 Diabetes Mellitus, Regardless of Age, Race, Sex, or Severity of Hypertension
Subgroup Analysis of the BENIFICIARY Study
verfasst von
Dr Joel M. Neutel
Dean J. Kereiakes
The BENIFICIARY Investigators
Publikationsdatum
01.10.2010
Verlag
Springer International Publishing
Erschienen in
American Journal of Cardiovascular Drugs / Ausgabe 5/2010
Print ISSN: 1175-3277
Elektronische ISSN: 1179-187X
DOI
https://doi.org/10.2165/11584690-000000000-00000

Weitere Artikel der Ausgabe 5/2010

American Journal of Cardiovascular Drugs 5/2010 Zur Ausgabe

Adis Drug Profile

Candesartan Cilexetil

Beutel versus Maschine: Beste Beatmungstechnik bei Herzstillstand gesucht

02.05.2024 Kardiopulmonale Reanimation Nachrichten

Stehen die Chancen auf eine Rückkehr der Spontanzirkulation nach Herz-Kreislauf-Stillstand bei manueller oder maschineller Beatmung besser? Und unterscheidet sich das neurologische Outcome nach der Reanimation? Das belgische Herzstillstand-Register liefert die Daten für einen direkten Vergleich zwischen Beutel und Beatmungsgerät.

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.